|
|
|
After three decades of the War on Cancer, progress in developing therapies has been disappointing. But the relative success of Gleevec in the treatment of chronic myelogenous leukaemia marks something of a milestone. In the 10 months since its introduction in the United States, it has shown that molecularly targeted drugs have a promising future.
A News Feature in this issue of Nature (Vol. 416, No. 6880, 04 Apr 02) reviews progress in converting our knowledge of molecular biology and genomics into advanced diagnostic and therapeutic tools. (C) Nature press release.
Message posted by: Trevor M. D'Souza
|
|
Variants Associated with Pediatric Allergic Disorder
Mutations in PHF6 Found in T-Cell Leukemia
Genetic Risk Variant for Urinary Bladder Cancer
Antibody Has Therapeutic Effect on Mice with ALS
Regulating P53 Activity in Cancer Cells
Anti-RNA Therapy Counters Breast Cancer Spread
Mitochondrial DNA Diversity
The Power of RNA Sequencing
‘Pro-Ageing' Therapy for Cancer?
Niche Genetics Influence Leukaemia
Molecular Biology: Clinical Promise for RNA Interference
Chemoprevention Cocktail for Colon Cancer
more news ...
|